PhRMA Launches National Campaign to Increase Diversity in Clinical Trials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PhRMA Launches National Campaign to Increase Diversity in Clinical Trials
The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 4

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum have developed a national campaign to help increase diversity in clinical trials.

The I’m In campaign will raise awareness about the importance of clinical research and increase participation by diverse patient populations to help researchers develop potential new medicines. Partnerships with patient advocacy organizations, provider groups, individual physicians, clinical trials sponsors, and researchers will help to drive campaign awareness and involvement.

According to FDA, African Americans represent 12% of the US population but only 5% of clinical trial participants and Hispanics make up 16% of the population but only 1% of clinical trial participants. Inclusion of individuals of varied races, ethnicities, ages, gender, and sexual orientation in clinical trials can help to prevent disparities in the evaluation of potential new medicines.

I’m In will support the National Minority Quality Forum’s Clinical Trial Engagement Network, a solution to help accelerate the inclusion of underrepresented populations in clinical trials. Authorized users will be able to identify potential clinical trial participants by using zip code level mapping of disease clusters and simultaneously identifying and connecting points of care and community resources that can assist with site selection and patient recruitment.

Source: Pharmaceutical Research and Manufacturers of America

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here